Enterprise Value

2.679M

Cash

1.337M

Avg Qtr Burn

-9.248M

Short % of Float

2.22%

Insider Ownership

18.61%

Institutional Own.

6.60%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
MB-107 Details
X-Linked severe combined immunodeficiency

Phase 2

Update

MB-207 Details
X-Linked severe combined immunodeficiency, Myelofibrosis

Phase 2

Update

MB-106 (CD20) (Mustang Multicenter) Details
Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Cancer, Lymphoma

Phase 2

Initiation

MB-106 (CD20) (Fred Hutch) Details
Lymphoma, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Epstein-Barr virus, Multiple sclerosis, Cancer, Waldenstrom macroglobulinemia

Phase 1/2

Update

MB-101 (IL-13Ra2) + MB-108 Details
Medulloblastoma, Ependymoma, Glioblastoma, Leptomeningeal brain tumors

Phase 1

Initiation

MB-103 (HER2) Details
Glioblastoma, Metastatic breast cancer to brain, Cancer

Failed

Discontinued

MB-104 Details
Multiple myeloma, Cancer, Solid tumor/s

Failed

Discontinued

MB-105 (PSCA) Details
Prostate cancer, Multiple myeloma, Cancer

Failed

Discontinued

MB-102 (CD123) Details
High risk myelodysplastic syndromes , Blastic plasmacytoid dendritic cell neoplasm, Acute myeloid leukemia, Cancer

Failed

Discontinued

MB-110 (LV-RAG1) Details
Severe combined immunodeficiency due to complete RAG1/2 deficiency

Failed

Discontinued